CN110573525A - 用抗tslp抗体治疗哮喘 - Google Patents

用抗tslp抗体治疗哮喘 Download PDF

Info

Publication number
CN110573525A
CN110573525A CN201880026131.3A CN201880026131A CN110573525A CN 110573525 A CN110573525 A CN 110573525A CN 201880026131 A CN201880026131 A CN 201880026131A CN 110573525 A CN110573525 A CN 110573525A
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
ser
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880026131.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·R·帕尼斯
J·格里菲思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Midi Muni Co Ltd
Amgen Inc
Original Assignee
Midi Muni Co Ltd
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midi Muni Co Ltd, Amgen Inc filed Critical Midi Muni Co Ltd
Publication of CN110573525A publication Critical patent/CN110573525A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201880026131.3A 2017-04-12 2018-04-12 用抗tslp抗体治疗哮喘 Pending CN110573525A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US62/484,864 2017-04-12
US201762553477P 2017-09-01 2017-09-01
US201762553575P 2017-09-01 2017-09-01
US62/553,477 2017-09-01
US62/553,575 2017-09-01
PCT/US2018/027271 WO2018191479A1 (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Publications (1)

Publication Number Publication Date
CN110573525A true CN110573525A (zh) 2019-12-13

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880026131.3A Pending CN110573525A (zh) 2017-04-12 2018-04-12 用抗tslp抗体治疗哮喘

Country Status (22)

Country Link
US (3) US10828365B2 (https=)
EP (1) EP3609917A1 (https=)
JP (4) JP7330896B2 (https=)
KR (2) KR102666879B1 (https=)
CN (1) CN110573525A (https=)
AU (2) AU2018253118B2 (https=)
BR (1) BR112019021482A2 (https=)
CA (1) CA3059364A1 (https=)
CL (1) CL2019002897A1 (https=)
CO (1) CO2019011462A2 (https=)
IL (1) IL269791B (https=)
JO (1) JOP20190243B1 (https=)
MX (1) MX2019012158A (https=)
MY (1) MY207509A (https=)
PE (1) PE20200484A1 (https=)
PH (1) PH12019502331A1 (https=)
SG (1) SG11201909322VA (https=)
TN (1) TN2019000289A1 (https=)
TW (2) TW202523688A (https=)
UA (1) UA130334C2 (https=)
UY (1) UY37676A (https=)
WO (1) WO2018191479A1 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
CN113501878A (zh) * 2021-02-03 2021-10-15 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN113683694A (zh) * 2021-09-03 2021-11-23 江苏荃信生物医药有限公司 一种抗人tslp单克隆抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN114853888A (zh) * 2021-02-05 2022-08-05 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
WO2022184074A1 (zh) * 2021-03-03 2022-09-09 正大天晴药业集团股份有限公司 含抗tslp抗体的药物组合物
CN115151276A (zh) * 2020-02-18 2022-10-04 安进公司 人抗tslp抗体的配制品及其使用方法
CN115279404A (zh) * 2020-02-13 2022-11-01 安进公司 人抗tslp抗体的配制品及治疗炎性疾病的方法
CN116217724A (zh) * 2021-12-02 2023-06-06 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
CN117551195A (zh) * 2024-01-12 2024-02-13 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210650T1 (hr) * 2015-09-09 2021-05-28 Novartis Ag Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
JP7628966B2 (ja) 2019-06-04 2025-02-12 ジエンス ヘンルイ メデイシンカンパニー リミテッド 胸線間質性リンパ球増殖因子に結合可能な抗体およびその使用
CA3147044A1 (en) * 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
EP4025602A4 (en) * 2019-09-04 2023-12-13 Biosion, Inc. TSLP BINDING ANTIBODIES AND USES THEREOF
PH12022551022A1 (en) * 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
CN114887053B (zh) * 2019-11-29 2026-04-24 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
AU2020400221A1 (en) * 2019-12-13 2022-05-19 Harbour Biomed (Shanghai) Co., Ltd. Anti-TSLP antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4103605A1 (en) * 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
PH12023552762A1 (en) * 2021-04-19 2024-04-15 Medimmune Ltd An anti-tslp fab with improved stability
KR20230175245A (ko) 2021-04-23 2023-12-29 암젠 인크 변형된 항-tslp 항체
EP4326766A1 (en) * 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗ｔｓｌｐ抗體組成物及其用途
WO2025049343A1 (en) * 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-tslp antibody constructs and uses thereof
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
US20260098100A1 (en) * 2024-10-04 2026-04-09 Prana Therapies, Inc. Il-4r and tslp inhibitors and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090238823A1 (en) * 2007-09-10 2009-09-24 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2016023019A2 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US20170066823A1 (en) * 2015-09-09 2017-03-09 Matthew John EDWARDS Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
US20170067108A1 (en) * 2013-10-23 2017-03-09 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
ES2784123T3 (es) 2009-11-04 2020-09-22 Merck Sharp & Dohme Anticuerpo anti TSLP genomodificado
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
KR20170123315A (ko) * 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090238823A1 (en) * 2007-09-10 2009-09-24 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CN101809035A (zh) * 2007-09-10 2010-08-18 安美基公司 能结合胸腺基质淋巴细胞生成素的抗原结合蛋白
US20170067108A1 (en) * 2013-10-23 2017-03-09 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
WO2016023019A2 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
US20170066823A1 (en) * 2015-09-09 2017-03-09 Matthew John EDWARDS Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GAIL M GAUVREAU等: "Effects of an anti-TSLP antibody on allergen-induced asthmatic responses", 《N ENGL J MED》 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115279404A (zh) * 2020-02-13 2022-11-01 安进公司 人抗tslp抗体的配制品及治疗炎性疾病的方法
CN115151276A (zh) * 2020-02-18 2022-10-04 安进公司 人抗tslp抗体的配制品及其使用方法
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878A (zh) * 2021-02-03 2021-10-15 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
CN114853888A (zh) * 2021-02-05 2022-08-05 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
WO2022184074A1 (zh) * 2021-03-03 2022-09-09 正大天晴药业集团股份有限公司 含抗tslp抗体的药物组合物
CN116897053A (zh) * 2021-03-03 2023-10-17 正大天晴药业集团股份有限公司 含抗tslp抗体的药物组合物
CN113683694A (zh) * 2021-09-03 2021-11-23 江苏荃信生物医药有限公司 一种抗人tslp单克隆抗体及其应用
US12378309B2 (en) 2021-09-03 2025-08-05 Qyuns Therapeutics Co., Ltd. Anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and use thereof to treat disease
CN116217724A (zh) * 2021-12-02 2023-06-06 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN116217724B (zh) * 2021-12-02 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
CN117551195A (zh) * 2024-01-12 2024-02-13 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用

Also Published As

Publication number Publication date
CA3059364A1 (en) 2018-10-18
AU2018253118B2 (en) 2025-04-10
CO2019011462A2 (es) 2019-10-31
JP2025170430A (ja) 2025-11-18
IL269791A (en) 2019-11-28
WO2018191479A1 (en) 2018-10-18
MY207509A (en) 2025-02-28
KR102666879B1 (ko) 2024-05-23
TW201838652A (zh) 2018-11-01
US20210052726A1 (en) 2021-02-25
CL2019002897A1 (es) 2020-03-06
BR112019021482A2 (pt) 2020-05-12
US20250032608A1 (en) 2025-01-30
AU2018253118A1 (en) 2019-10-24
KR20240070727A (ko) 2024-05-21
AU2025204735A1 (en) 2025-07-17
JP2023099233A (ja) 2023-07-11
KR20190140956A (ko) 2019-12-20
JP7330896B2 (ja) 2023-08-22
SG11201909322VA (en) 2019-11-28
JOP20190243A1 (ar) 2019-10-13
JP2020516647A (ja) 2020-06-11
TN2019000289A1 (en) 2021-05-07
PE20200484A1 (es) 2020-03-03
US10828365B2 (en) 2020-11-10
JP2024150751A (ja) 2024-10-23
IL269791B (en) 2022-07-01
US20180296669A1 (en) 2018-10-18
JOP20190243B1 (ar) 2024-12-22
PH12019502331A1 (en) 2020-09-28
MX2019012158A (es) 2019-12-16
UY37676A (es) 2018-10-31
TW202523688A (zh) 2025-06-16
EP3609917A1 (en) 2020-02-19
UA130334C2 (uk) 2026-01-28
TWI856945B (zh) 2024-10-01

Similar Documents

Publication Publication Date Title
US20250032608A1 (en) Treatment of asthma with anti-tsl p antibody
EP2627673B1 (en) Therapies for improving pulmonary function
TW202304980A (zh) 經修飾的抗ｔｓｌｐ抗體
CN115151276A (zh) 人抗tslp抗体的配制品及其使用方法
US20230073888A1 (en) Treatment of atopic dermatitis with anti-tslp antibody
US20240360210A1 (en) Use of an il-18 antagonist for treating and/or prevention of atopic dermatitis or a related condition
KR20260013478A (ko) 항-tslp 항체를 사용한 코르티코스테로이드 의존성 천식의 치료
KR20250140101A (ko) 항-tslp 항체를 이용한 만성 비부비동염의 치료
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
WO2025221247A1 (en) Treatment of eosinophilic esophagitis with anti-tslp antibody
US20140248289A1 (en) Methods and Compositions for the Treatment of Respiratory Conditions Via NKG2D Inhibition
JP2019515902A (ja) Ｉｌｃ２、免疫、およびｃｏｐｄの機能的可塑性

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination